Maze Therapeutics (MAZE) Cash & Equivalents (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Cash & Equivalents data on file, last reported at $198.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 32.48% year-over-year to $198.8 million; the trailing twelve-month figure through Mar 2026 stood at $198.8 million (down 32.48% YoY), and the FY2025 full-year result was $189.2 million, down 3.84% from the prior year.
• Cash & Equivalents grew to $198.8 million in Q1 2026, from $189.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $316.8 million in Q3 2025 to a low of $30.0 million in Q1 2024.
• A 3-year average of $201.7 million and a median of $196.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 880.49% in 2025 and plunged 32.48% in 2026, its largest moves.
• Tracing MAZE's Cash & Equivalents over 3 years: stood at $196.8 million in 2024, then dropped by 3.84% to $189.2 million in 2025, then increased by 5.03% to $198.8 million in 2026.
• Business Quant data shows MAZE's Cash & Equivalents at $198.8 million in Q1 2026, $189.2 million in Q4 2025, and $316.8 million in Q3 2025.